Edwards Lifesciences Announces FTC Move to Block JenaValve Acquisition

Details

Federal Trade Commission (FTC) has moved to block its proposed acquisition of JenaValve Technology, Inc. The company disagrees with the FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). Edwards intends to continue pursuing regulatory approval and has revised its full-year 2025 financial guidance, increasing its adjusted Earnings Per Share (EPS) guidance to the high-end of $2.45-$2.55.

Items reported

Exhibits (1)

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.